Home | Recruitment

Pending

Trials by recruitment status

Public Titlesort icon Date of registration Sponsor
Oncoxin®-Viusid®- Quality of life of patients with metastatic colorectal adenocarcinoma-adults-Phase II 05/06/2018 CATALYSIS
Paclitaxel/Radiotherapy/Cisplatino for cervical cancer 17/02/2017 SSA
Phase I/II trial with the mutein no alfa of IL-2 03/02/2017 CIM
Phase II clinical trial, controlled, randomized, double-blind to assess the immunogenicity of live attenuated vaccine candidate against cholera CV638 . 06/11/2014 FINLAY
Phase III clinical trial: Dermofural®. Mild infection in diabetic foot ulcer 24/04/2023 CBQ
Phase III study of the Cuban vaccine candidate VCN7-T in patients from 1 to 18 years of age at risk of pneumococcal disease in Havana 04/10/2023 FINLAY
Phyisician Led CIMAvax-EGF lung biomarkers 11/03/2021 CIM
Policosanol + aspirin in post-stroke cognitive impairment 30/06/2021 CPN
Policosanol in patients with metabolic syndrome and ischaemic cardiopaty 27/12/2016 CPN
Policosanol in patients with pre-hypertension or with grade I hypertension 30/06/2021 CPN
Policosanol-Atorvastatina for Ictus 02/09/2013 CPN
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX 21/05/2021 CIM
Quality of life and safety of CARMINAL® nutritional supplement in patients with mild or moderate ulcerative colitis 29/02/2024 CATALYSIS
Quality of Life and safety of the nutritional supplement Deprexil® or Placebo in combination with cognitive stimulation treatment in patients with Mild Cognitive Impairment and Mild Alzheimer's Dementia. 07/03/2024 CATALYSIS
Quimi-Hib® and Quimi-Hib(AlPO4) vaccines in an accelerated 6-10-14 weeks primary vaccination series 2012-09-12 CIGB
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory 09/07/2018 CIM
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients 15/12/2015 CIM
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer 08/07/2015 CIM
Rectal Ozone in the COVID-19 treatment 05/06/2020 CPN
Rectal ozone therapy in high-risk symptomatic SARS-CoV-2 positive patients 15/07/2021 CPN